Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors

被引:459
作者
Shaked, Yuval
Ciarrocchi, Alessia
Franco, Marcela
Lee, Christina R.
Man, Shan
Cheung, Alison M.
Hicklin, Daniel J.
Chaplin, David
Foster, F. Stuart
Benezra, Robert
Kerbel, Robert S. [1 ]
机构
[1] Sunnybrook Hlth Sci Ctr, Dept Mol & Cellular Biol Res, Toronto, ON M4N 3M5, Canada
[2] Mem Sloan Kettering Canc Ctr, Program Canc Biol & Genet, New York, NY 10021 USA
[3] Sunnybrook Hlth Sci Ctr, Dept Imaging Res, Toronto, ON M4N 3M5, Canada
[4] ImClone Syst, New York, NY 10014 USA
[5] OXiGENE Inc, Waltham, MA 02451 USA
关键词
D O I
10.1126/science.1127592
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The contribution of bone marrow-derived circulating endothelial progenitor cells (CEPs) to tumor angiogenesis has been controversial, primarily because of their low numbers in blood vessels of untreated tumors. We show that treatment of tumor-bearing mice with vascular disrupting agents (VDAs) leads to an acute mobilization of CEPs, which home to the viable tumor rim that characteristically remains after such therapy. Disruption of this CEP spike by antiangiogenic drugs or by genetic manipulation resulted in marked reductions in tumor rim size and blood flow as well as enhanced VDA antitumor activity. These findings also provide a mechanistic rationale for the enhanced efficacy of VDAs when combined with antiangiogenic drugs.
引用
收藏
页码:1785 / 1787
页数:3
相关论文
共 19 条
[11]  
Prewett M, 1999, CANCER RES, V59, P5209
[12]   Vascular and haematopoietic stem cells:: Novel targets for anti-angiogenesis therapy? [J].
Rafii, S ;
Lyden, D ;
Benezra, R ;
Hattorï, K ;
Heissig, B .
NATURE REVIEWS CANCER, 2002, 2 (11) :826-835
[13]   Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors [J].
Ruzinova, MB ;
Schoer, RA ;
Gerald, W ;
Egan, JE ;
Pandolfi, PP ;
Rafii, S ;
Manova, K ;
Mittal, V ;
Benezra, R .
CANCER CELL, 2003, 4 (04) :277-289
[14]   Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis [J].
Shaked, Y ;
Bertolini, F ;
Man, S ;
Rogers, MS ;
Cervi, D ;
Foutz, T ;
Rawn, K ;
Voskas, D ;
Dumont, DJ ;
Ben-David, Y ;
Lawler, J ;
Henkin, J ;
Huber, J ;
Hicklin, DJ ;
D'Amato, RJ ;
Kerbel, RS .
CANCER CELL, 2005, 7 (01) :101-111
[15]   Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy [J].
Shaked, Y ;
Emmenegger, U ;
Francia, G ;
Chen, L ;
Lee, CR ;
Man, S ;
Paraghamian, A ;
Ben-David, Y ;
Kerbel, RS .
CANCER RESEARCH, 2005, 65 (16) :7045-7051
[16]   Vascular-targeting therapies for treatment of malignant disease [J].
Siemann, DW ;
Chaplin, DJ ;
Horsman, MR .
CANCER, 2004, 100 (12) :2491-2499
[17]   The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors [J].
Siemann, DW ;
Rojiani, AM .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (03) :846-853
[18]   Disrupting tumour blood vessels [J].
Tozer, GM ;
Kanthou, C ;
Baguley, BC .
NATURE REVIEWS CANCER, 2005, 5 (06) :423-435
[19]   Endothelial progenitor cells - Characterization and role in vascular biology [J].
Urbich, C ;
Dimmeler, S .
CIRCULATION RESEARCH, 2004, 95 (04) :343-353